What is Trialbee?
Founded in 2010 and headquartered in Malmö, Sweden, Trialbee is a dynamic software company dedicated to accelerating clinical research. Its innovative software solutions are designed to streamline the clinical trial process by providing a unified platform for seamless communication and collaboration among all involved parties. Trialbee's technology addresses critical needs in the life sciences sector, aiming to reduce timelines and improve efficiencies in bringing new treatments to market. The company's focus on optimizing trial operations positions it as a key player in the digital health and clinical research technology landscape.
How much funding has Trialbee raised?
Trialbee has raised a total of $20.3M across 3 funding rounds:
Unspecified
$3.3M
Series A
$5M
Other Financing Round
$12M
Unspecified (2013): $3.3M, investors not publicly disclosed
Series A (2015): $5M led by Industrifonden
Other Financing Round (2020): $12M supported by Briban Invest AB and MTIP AG
Key Investors in Trialbee
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science. The fund focuses on areas such as deep tech, life sciences, and transformative tech, partnering with passionate founders to bring their ideas to life. With a commitment to long-term support, Industrifonden backs transformative ventures that have the potential to change industries or create entirely new ones. Their portfolio includes companies in various sectors, including biotech, telecom, and sustainable manufacturing.
Briban Invest AB
Briban Invest AB is an investment entity that has participated in Trialbee's funding rounds. Further details on their specific investment focus or sector specialization are not publicly available, but their involvement suggests a strategic interest in the clinical research technology space.
MTIP AG
MTIP AG is an investment firm that has backed Trialbee. While specific details about MTIP AG's investment thesis are not provided, their participation indicates a potential focus on technology-driven companies within the healthcare or life sciences sectors.
What's next for Trialbee?
The recent major strategic investment in Trialbee signals a strong validation of its business model and its potential for significant growth within the clinical research technology sector. This capital infusion is expected to fuel further development of its collaborative platform, enhance market penetration, and potentially expand its service offerings. As Trialbee continues to scale, its focus will likely remain on empowering stakeholders with advanced tools for more efficient and effective clinical trials, thereby contributing to the faster delivery of medical innovations. The company's trajectory suggests a move towards broader enterprise adoption and deeper integration within the global clinical research ecosystem.
See full Trialbee company page
